“…(Abbreviations used: ATPA, (RS)-2-amino-3(3-hydroxy-5-t butylisoxazol-4-yl) propanionate; GYKI 52466, 1-(4-amino-phenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine; SYM2206, (±)-4-(4-aminophenyl)-1,2-dihydro-1-methyl-2-propylcarbamoyl-6,7-methylenedioxyphthalazine.) (Abbreviations used: APDC, 2R,4R-4-aminopyrrolidine-2,4-decarboxylate; CCG-1, (2S,19S,29S)-2-(2-carboxycyclopropyl) glycine; CHPG, 2-chloro-5-hydroxyphenylglycine; 4CPG, (S)-4-carboxyphenylglycine; CPPG, a-cyclopropyl-4-phosphonophenylglycine; DHPG, 3,5-dihydroxyphenylglycine; l-AP4, l-2-amino-4-phosphonobutyric acid; l-SOP, l-serine-O-phosphate; LY341495, 2S-2-amino-2 (1S,2S-2-carboxcyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid; LY354740, (1) of NMDA receptors and non-NMDA ionotropic receptors (Salt 1986;Crunelli et al 1987;Sillito et al 1990;Salt & Eaton 1991;, and it has become clear that this re ects a fast EPSP/C component mediated by AMPA receptors in conjunction with an NMDAreceptor-mediated synaptic component (Paulsen & Heggelund 1994;Turner et al 1994;Turner & Salt 1998;Kielland & Heggelund 2001). These in vivo and in vitro electrophysiological ndings are supported by ultrastructural evidence showing the localization of NMDA and AMPA receptor subunits postsynaptic to sensory terminals (Liu 1997;Mineff & Weinberg 2000).…”